Ikaria® To Present At Wedbush Securities 2012 Life Sciences Management Access Conference

HAMPTON, N.J., Aug. 7, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients, today announced that its Chairman and CEO, Daniel Tassé, will present at the Wedbush Securities 2012 Life Sciences Management Access Conference at Le Parker Meridien Hotel in New York, NY.  Mr. Tassé will give an overview of Ikaria's lead product, the INOMAX® Therapy Package, and the company's significant late-stage pipeline on Tuesday, August 14, 2012 from 12:45 to 1:15 p.m. EDT in the Gamshoge.  

About Ikaria, Inc.

Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is investigating additional indications for INOMAX in bronchopulmonary dysplasia, and for inhaled nitric oxide with the INOpulse® DS drug-delivery system as a drug-device combination product in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD). Ikaria's late-stage pipeline is also comprised of Terlipressin, a potential treatment for Hepatorenal Syndrome Type 1, which is currently approved and marketed in Australia; as well as Bioabsorbable Cardiac Matrix (BCM), a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with a research facility in Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com

SOURCE Ikaria, Inc.